Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 2, 2013Cancer Chemotherapy and PharmacologyOpen Access

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

View Full Paper
Ask AI
Bookmark
Share

Authors

ATAnthony W. TolcherTexas OncologyWRWendi V. RodriguezaEsperion Therapeutics (United States)DRDrew RascoSouth Texas Accelerated Research Therapeutics

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tolcher et al. (2013) studied this question.

synapsesocial.com/papers/6a07955b5ca7144909c645fehttps://doi.org/10.1007/s00280-013-2361-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor2008 · 2,006 citations
  2. 2Target mRNA inhibition by oligonucleotide drugs in man2012 · 36 citations
  3. 3Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)2004 · 72 citations
  4. 4Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease2011 · 833 citations
  5. 5Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL2011 · 123 citations